LSH earnings analysis
What we found in LSH's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Lakeside Holding Limited reported significant growth in Q2 2026 with revenue reaching $7 million, a 75% increase from Q1, and a notable improvement in gross margin to 27.2%. However, despite the revenue growth, the company continues to operate at a loss with diluted EPS recorded at -0.08. Management has highlighted ongoing challenges related to regulatory pressures in China and a considerable loan receivable impacting liquidity.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth of 75% in Q2 2026
- Lakeside's revenue surged to $7 million for Q2 2026, up from $4 million in Q1, driven by pharmaceutical distribution business expansion.
- Improvement in Gross Margin
- Gross margin increased to 27.2% in Q2 2026, up from 18.2% in Q1 2026, indicating better cost management.
- Increase in Active Customers
- The number of active customers rose from 4 to 12 during Q2 2026, contributing to increased sales volume.
- Decrease in Interest Expense
- Interest expenses decreased to $26,733 in Q2 2026 from $40,541 in Q1 2026, reflecting reduced financing costs.
- Liquidity Position Improved
- Current assets increased to approximately $17 million as of March 31, 2026, compared to $10 million in June 2025, enhancing liquidity.
- Gain from Discontinued Operations
- A gain of $2,556,315 from the sale of ABL Chicago was recorded in Q2 2026, contributing positively to the overall financials.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Dependence on Loan Receivable
- Liquidity is significantly influenced by a $8.7 million loan receivable, representing 49% of total current assets.
- Regulatory Risks in China
- The pharmaceutical business operates under stringent regulations in China, which could affect pricing and sales.
- Continued Operating Losses
- Net loss from continuing operations was $3.5 million for the nine months ended March 31, 2026, indicating ongoing financial challenges.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.08
- Gross margin
- 27.2%
- Segment
- Pharmaceutical Distribution
What they said about what is next.
Management did not provide explicit guidance but pointed to continued focus on expanding the pharmaceutical distribution business.
The filing reads about the same as the one before it.
What came before.
- 10-Q · February 19, 2026
- Lakeside reported Q2 revenue of $7,012,633 and GAAP loss per share of $(0.08). Revenue and gross profit improved materially year-over-year (revenue +$3,417,044; gross profit swing +$1,952,524) while operating loss…
- 10-Q · November 19, 2025
- Lakeside reported quarterly revenue of $6,099,889 (up from $4,081,554 a year earlier) with gross profit of $1,108,767 and a narrower loss per share of $(0.09) versus $(0.18) in the year-ago quarter. However, the company…
- 10-Q · May 15, 2025
- Lakeside reported Q3 revenue of $3,803,140 and GAAP loss per share of $(0.14). Gross profit was $715,851 (≈18.8% of revenue) but operating loss widened to $(1,074,183) driven by a $1,680,339 increase in G&A for the…
- 10-Q · February 14, 2025
- Lakeside reported Q2 revenue of $3,595,589 (down from $4,916,103 a year earlier) and a GAAP loss per share of $(0.26). Gross profit for the quarter was a loss of $42,231 (gross margin ≈ -1.2%), and operating loss was…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing LSH makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever